Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies... Show more
The 10-day moving average for ADAP crossed bearishly below the 50-day moving average on October 28, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADAP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
a manufacturer of vaccines and cancer immunotherapy products
Industry Biotechnology